Abstract: A method for characterizing a well for control of a pump, comprising inputting well parameters, into a processor and generating from the input well parameters a well profile, the well profile having a plurality of statistically derived values, each said statistical value corresponding to respective operating points of the pump operational data, and each of the plurality of statistical values being derived from respective statistical analyses taken at the respective operating points, each of the plurality of statistical values being based on a respective analysis of a plurality of sampled well head data at a common point of the operating points.

Abstract: A method for determining flow in a medium, comprising applying thermal energy to at least one probe of a pair of probes, the probes configured for placement in the medium and varying the applied thermal energy of the at least one probe to maintain a constant temperature differential between the pair of probes and determining a flow from the applied thermal energy while maintaining the constant temperature differential.

Abstract: The present invention relates to the use of a mixture of the enantiomers of a compound of formula I or of pharmaceutically acceptable salts of said enantiomers consisting of at least 55% of the R-enantiomer, most preferably of at least 98% of the R-enantiomer, and not more than 45% of the S-enantiomer, most preferably not more than 2% of the S-enantiomer, for the manufacture of a pharmaceutical composition for the treatment of neuropathic pain; to a method for the treatment of neuropathic pain; and to a pharmaceutical composition comprising as active agent a mixture of the enantiomers of the compound of formula I or pharmaceutically acceptable salts of said enantiomers consisting of at least 55% of the R-enantiomer and not more than 45% of the S-enantiomer.

Abstract: This invention provides novel genes and polypeptides of the transient receptor potential channel family, and use of these genes and polypeptides for the treatment of pain and identification of agents useful in the treatment of pain.

Abstract: The methods and compositions of the invention are based on a method for measuring nociceptive responses in vertebrates, including humans and other mammals utilizing a newly discovered thermoreceptor belonging to the Transient Receptor Potential (TRP) family of non-selective cation channels that participates in thermosensation and pain. This receptor, designated ANKTM1, is associated with nociceptive pain, such as hyperalgesia. Accordingly, the invention provides isolated polypeptides and polynucleotides associated with nociception as well as methods for identifying or screening agents that modulate nociception.

Abstract: The present invention relates to the use of a mixture of the enantiomers of a compound of Formula (I) or of pharmaceutically acceptable salts of said enantiomers consisting of at least 55% of the R-enantiomer, most preferably of at least 98% of the R-enantiomer, and not more than 45 % of the S-enantiomer, most preferably not more than 2% of the S-enantiomer, for the manufacture of a pharmaceutical composition for the treatment of neuropathic pain; to a method for the treatment of neuropathic pain; and to a pharmaceutical composition comprising as active agent a mixture of the enantiomers of the compound of formula I or pharmaceutically acceptable salts of said enantiomers consisting of at least 55% of the R-enantiomer and not more than 45% of the S-enantiomer.

Abstract: The methods and compositions of the invention are based on a method for measuring nociceptive responses in vertebrates, including humans and other mammals utilizing a newly discovered thermoreceptor belonging to the Transient Receptor Potential (TRP) family of non-selective cation channels that participates in thermosensation and pain. This receptor, designated ANKTMI, is associated with nociceptive pain, such as hyperalgesia. Accordingly, the invention provides isolated polypeptides and polynucleotides associated with nociception as well as methods for identifying or screening agents that modulate nociception.

Abstract: This invention provides novel genes and polypeptides of the transient receptor potential channel family, and use of these genes and polypeptides for the treatment of pain and identification of agents useful in the treatment of pain.

Abstract: This invention provides novel genes and polypeptides of the transient receptor potential channel family, and use of these genes and polypeptides for the treatment of pain and identification of agents useful in the treatment of pain.

Abstract: This invention provides novel genes and polypeptides of the transient receptor potential channel family, and use of these genes and polypeptides for the treatment of pain and identification of agents useful in the treatment of pain.

Abstract: This invention provides novel genes and polypeptides of the VR family, identification of trkA+ pain specific genes expressed in the DRG, and use of these genes and polypeptides for the treatment of pain and identification of agents useful in the treatment of pain.

Abstract: A controller for controlling the pump unit of an oil well includes a sensor having a first and second probe for placement in the flow of oil from the well bore. Each of the probes contains a heater. A constant power source is selectively connected to one of the heaters. Each of the probes also includes a linear RTD at each of their tips respectively for generating a signal indicative of the temperature measured at each of the first and second probes. A control unit receives signals from the RTD's and determines a flow rate therefrom. A pump control signal is generated in response to the flow rate, wherein the pump control signal continuously varies a predetermined parameter for controlling the flow rate of a pumping unit during operation of the pumping unit.

Abstract: The present invention relates to the use of a mixture of the enantiomers of a compound of Formula (I) or of pharmaceutically acceptable salts of said enantiomers consisting of at least 55% of the R-enantiomer, most preferably of at least 98% of the R-enantiomer, and not more than 45 % of the S-enantiomer, most preferably not more than 2% of the Senantiomer, for the manufacture of a pharmaceutical composition for the treatment of neuropathic pain; to a method for the treatment of neuropathic pain; and to a pharmaceutical composition comprising as active agent a mixture of the enantiomers of the compound of formula I or pharmaceutically acceptable salts of said enantiomers consisting of at least 55% of the R-enantiomer and not more than 45% of the S-enantiomer.

Abstract: The methods and compositions of the invention are based on a method for measuring nociceptive responses in vertebrates, including humans and other mammals utilizing a newly discovered thermoreceptor belonging to the Transient Receptor Potential (TRP) family of non-selective cation channels that participates in thermosensation and pain. This receptor, designated ANKTMI, is associated with nociceptive pain, such as hyperalgesia. Accordingly, the invention provides isolated polypeptides and polynucleotides associated with nociception as well as methods for identifying or screening agents that modulate nociception.

Abstract: A controller for controlling the pump unit of an oil well includes a sensor having a first and second probe for placement in the flow of oil from the well bore. Each of the probes contains a heater. A constant power source is selectively connected to one of the heaters. Each of the probes also include a linear RTD at each of their tips respectively for generating a signal indicative of the temperature measured at each of the first and second probes. A control unit receives signals from the RTD's and determines a flow rate therefrom. A pump control signal is generated in response to the flow rate, wherein pump control signal continuously varies a predetermined parameter of a pumping unit during operation of the pumping unit.

Abstract: This invention provides novel genes and polypeptides of the VR family, identification of trkA+ pain specific genes expressed in the DRG, and use of these genes and polypeptides for the treatment of pain and identification of agents useful in the treatment of pain.